Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06365047 · ClinicalTrials.gov registry record · Phase 3
Dry Mouth Toothpaste Study - Comparing Two Toothpastes With Arginine
A Phase 3 study of Xerostomia, sponsored by Tufts University.
- Active
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06365047: Active Phase 3 study of Xerostomia, sponsored by Tufts University.
NCT06365047 is a Phase 3 study of Xerostomia that is active but no longer recruiting, run by Tufts University. The registered enrollment target is 70 participants, below the 90-participant average among 13 other Xerostomia trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06365047, a Phase 3 study of Xerostomia, is active but no longer recruiting, sponsored by Tufts University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a clinical investigation to measure the changes in the oral environment resulting from a 3 month exposure to an arginine containing toothpaste. This study is a double blind, randomized controlled, parallel design. Seventy (70) male and female subjects who meet the inclusion/exclusion criteria will be enrolled in the study. Following oral health evaluations, subjects will be assigned to the treatment schedule and receive their assigned study product.
Primary Outcome
The objective of this clinical research study is to determine if the use of an Arginine containing toothpaste alters the salivary pH of people with xerostomia.
Conditions Studied
Interventions
- DEVICE 8% Arginine toothpaste
- DRUG 1000 ppm F toothpaste
Study Locations (1)
Massachusetts
- Tufts University School of Dental Medicine - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-08-31 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 3 |
What the registry record for NCT06365047 still lists
NCT06365047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 90-participant average among 13 other Xerostomia trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Xerostomia appearing as the primary indexed condition, and to 2 interventions - of which 8% Arginine toothpaste is the first listed.
NCT06365047 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06365047 about?
NCT06365047 is a clinical study titled "Dry Mouth Toothpaste Study - Comparing Two Toothpastes With Arginine". This is a clinical investigation to measure the changes in the oral environment resulting from a 3 month exposure to an arginine containing toothpaste. This study is a double blind, randomized controlled, parallel design. Seventy (70) male and female subjects who meet the inclusion/exclusion criteri...
What is the current status of trial NCT06365047?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2024-08-31. Estimated completion is 2028-06-01.
What conditions does trial NCT06365047 study?
This clinical trial studies the following conditions: Xerostomia.
What interventions are being tested in trial NCT06365047?
The interventions under investigation include: 8% Arginine toothpaste (DEVICE), 1000 ppm F toothpaste (DRUG).
Who is sponsoring clinical trial NCT06365047?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06365047 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Xerostomia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06365047's enrollment target sits among peer trials
70 4th of 13 higher than 9 of 13 other Xerostomia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Xerostomia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC
RECRUITING · Phase 1
-
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
RECRUITING · Phase 1
-
Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy
ACTIVE NOT RECRUITING · Phase 1
-
Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis
ACTIVE NOT RECRUITING · NA
-
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
ACTIVE NOT RECRUITING
-
Effect of Childhood Radioiodine Therapy on Salivary Function
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI